Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.
[Lyell Immunopharma, Inc.]
7992332
BBBBBBBB
items
1
apa
0
default
asc
1
171091
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/